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793Abstracts
Patients previously diagnosed, suffering from a psychotic disor-
der or unable to follow-up the study were excluded. Three visits
were conducted per protocol (baseline, 6 and 12 months).
RESULTS: A total of 921 patients were included in the analysis.
Mean (SD) age was 74.3 (6.8) years and 66.9% were women.
First suspected diagnosis were: age related memory impairment
(17.5% of patients), cognitive impairment (21.9%), dementia
(29.2%), and psychopathological disorders (14.9%). Diagnostic
methods used were: anamnesis (96,2% of patients); physical and
neurological examination (87,5% and 85.6%), screening and
laboratory test (85.9% and 89%). In all, 630 patients attended
to at least one visit “out of protocol” to their PCP during the
follow-up period. Mean (SD) number of visits was 4.28 (3.1).
Percentile 25, 50, and 75 were 2, 3, and 6 visits respectively. The
visits were previously appointed by physicians (54.7%) or were
patients spontaneous consultations (39.7%). Main reason for
“out of protocol” visits were to evaluate patient evolution.
45.1% of patients were never derived, 36.9% and 18% were
derived to specialist once, or more than once, respectively. Main
reason was diagnostic conﬁrmation. CONCLUSION: Initial visit
of patients with memory complaints or cognitive impairment to
PCP, originate a careful follow-up of the patient. Different
number of diagnostic methods and high time consumer proce-
dures (as anamnesis, or screening test) have been applied. Deriva-
tions to specialist seem to be low.
NEUROLOGICAL DISORDERS (Migraine,Alzheimer’s,
Dementia)
NEUROLOGICAL DISORDERS (Migraine,Alzheimer’s,
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OBJECTIVES: To determine the psychometric properties of the
RLSQoL (V1.1) in a clinical trial setting. METHODS: Patient
populations from two matching, placebo-controlled, multina-
tional studies assessing the effectiveness and safety of ropinirole
for treating moderate-to-severe RLS formed the basis of a psy-
chometric assessment of the RLSQoL. Tests for validity and reli-
ability were performed using baseline data. Responsiveness was
determined using longitudinal, 12-week data. Tests were per-
formed on blinded, individual trial data. RESULTS: A total of
547 subjects formed the baseline validation population, 519
were used for assessing responsiveness (n = 284/271 and 263/248
for both studies, respectively). Construct validity assessment con-
ﬁrmed an overall life-impact score could be calculated (account-
ing for 39% and 46% of the variance in the two studies,
respectively). All items passed the test for item convergent valid-
ity (item-scale correlation ≥0.4), except items 1 “distress” (r =
0.36) and 5 “late for work/ﬁrst appointments” (r = 0.35) in one
study. There were no signiﬁcant missing data, ﬂoor or ceiling
effects for the RLSQoL overall life-impact score. Cronbach’s a
were 0.82 and 0.87, conﬁrming internal consistency reliability of
the scale. Concurrent validity was determined by correlation
with the International Restless Legs Scale, measuring similar
health constructs (r = -0.68, -0.67, p < 0.0001); known groups
validity by its ability to discriminate between subjects with dif-
ferent levels of sleep problems (p < 0.0001) and clinical validity
by its ability to discriminate between levels of global health
status determined by a Clinical Global Impression of severity
(CGI-S) (p < 0.0001). Responsiveness was demonstrated by sta-
tistically signiﬁcant differences in RLSQoL overall life-impact
change scores between CGI improvement levels after 12 weeks
of treatment (p < 0.0001; effect size range: 0.74–1.15 and
0.54–1.51 for improved groups). CONCLUSIONS: The
RLSQoL is a valid, reliable and responsive measure of quality of
life for patients with RLS when used in a clinical trial setting.
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OBJECTIVES: To develop a simple dichotomous scale for the
assessment of RLS severity to be used for facilitating therapeu-
tic decisions. METHODS: A prospective epidemiological study
was conducted in primary healthcare in France. First, patients
fulﬁlling the RLS diagnostic criteria from the International Rest-
less Legs Study Group were identiﬁed. Secondly, severity of iden-
tiﬁed RLS subjects was assessed using the IRLS rating scale. This
scale includes ten items, each rated on a ﬁve point Lickert scale
from zero to four (“non” to “very severe”) and summed in a
global score from zero to 40 (0–20: non-severe; 21–40: severe).
Using a segmentation analysis applied to the rating scale items
and other measures of RLS impact, we attempted to ﬁnd a small
number of items able to distinguish severe from non-severe RLS
patients as the rating scale would have done. RESULTS: A total
of 537 patients were analyzed. Three items came up from the
segmentation analysis, consolidated into “RS-3”. All three were
part of the rating scale. They dealt with: overall RLS severity,
overall sleep disturbance and mood disturbance. The decision
rule was that an answer zero,one or two (ie. none, mild or mod-
erate) to at least one of the three items assigned an RS-3 grade
of “non-severe”. The sensitivity and speciﬁcity of RS-3 were
82% and 95% respectively. The positive and negative predictive
values (PPV and NPV) were 92% and 88%. Sensitivity analyses
with thresholds of 15, 25 and 30 were performed without
improving sensitivity and speciﬁcity. The reproducibility of the
RS-3 was assessed in another RLS population (731 subjects from
the INSTANT Study) with sensitivity / speciﬁcity of 88% and
91%; and PPV and NPV of 73% and 97%, respectively. CON-
CLUSIONS: The metrology of the RS-3 scale appears to be
strong enough to be used in larger sample.
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OBJECTIVES: Dyskinesia is generally thought to severely affect
health-related quality of life (QoL) in patients with Parkinson’s
